Janux Therapeutics, Inc. (JANX) insider trading

By person

18 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

David Alan Campbell

President and CEO

—

264,742

$3.71M

−6.1%

Thomas DiRaimondo

Chief Scientific Officer

—

155,825

$2.19M

+51.4%

Sheila Gujrathi

Director

—

118,889

$1.67M

+3.3%

Charles M. Winter

Chief Technical Officer

—

106,321

$1.49M

+86.1%

Andrew Hollman Meyer

Chief Business Officer

—

83,095

$1.17M

+18.0%

Vickie L Capps

Director

—

79,598

$1.12M

+13.1%

Janeen Noel Doyle

Chief Corp. & Bus. Dev. Ofcr

—

75,941

$1.07M

—

Zachariah McIver

Chief Medical Officer

—

52,286

$733.52K

—

William Go

Chief Medical Officer

—

44,000

$617.28K

—

Maria Dobek

Vice President, Accounting

—

32,270

$452.72K

+1,038%

Byron Robinson

Chief Strategy Officer

—

28,000

$392.81K

—

Eric Dobmeier

Director

—

15,481

$217.18K

+148.5%

Natasha Hernday

Director

—

15,481

$217.18K

+148.5%

Ra Capital Management, L.p. entity

Director

—

11,750

$164.84K

—

Jake Simson

Director

—

11,750

$164.84K

+370.0%

Winston Kung

Director

—

11,750

$164.84K

+370.0%

Ronald W Barrett

Director

—

11,750

$164.84K

+370.0%

Alana B. McNulty

Director

—

6,250

$87.68K

+150.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Janux Therapeutics, Inc.

What the insiders did No buying or selling

By person